257 related articles for article (PubMed ID: 28456090)
1. Dynamic evaluation of circulating tumour cells in patients with advanced gastric and oesogastric junction adenocarcinoma: Prognostic value and early assessment of therapeutic effects.
Pernot S; Badoual C; Terme M; Castan F; Cazes A; Bouche O; Bennouna J; Francois E; Ghiringhelli F; De La Fouchardiere C; Samalin E; Bachet JB; Borg C; Ducreux M; Marcheteau E; Stanbury T; Gourgou S; Malka D; Taieb J
Eur J Cancer; 2017 Jul; 79():15-22. PubMed ID: 28456090
[TBL] [Abstract][Full Text] [Related]
2. Dynamic monitoring of circulating tumour cells to evaluate therapeutic efficacy in advanced gastric cancer.
Li Y; Gong J; Zhang Q; Lu Z; Gao J; Li Y; Cao Y; Shen L
Br J Cancer; 2016 Jan; 114(2):138-45. PubMed ID: 26784122
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of the combination of circulating tumor cells plus KRAS in patients with metastatic colorectal cancer treated with chemotherapy plus bevacizumab.
Sastre J; Vidaurreta M; Gómez A; Rivera F; Massutí B; López MR; Abad A; Gallen M; Benavides M; Aranda E; Rubio ED;
Clin Colorectal Cancer; 2013 Dec; 12(4):280-6. PubMed ID: 24012456
[TBL] [Abstract][Full Text] [Related]
4. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
Al-Batran SE; Hartmann JT; Probst S; Schmalenberg H; Hollerbach S; Hofheinz R; Rethwisch V; Seipelt G; Homann N; Wilhelm G; Schuch G; Stoehlmacher J; Derigs HG; Hegewisch-Becker S; Grossmann J; Pauligk C; Atmaca A; Bokemeyer C; Knuth A; Jäger E;
J Clin Oncol; 2008 Mar; 26(9):1435-42. PubMed ID: 18349393
[TBL] [Abstract][Full Text] [Related]
5. A multimarker panel for circulating tumor cells detection predicts patient outcome and therapy response in metastatic colorectal cancer.
Barbazán J; Muinelo-Romay L; Vieito M; Candamio S; Díaz-López A; Cano A; Gómez-Tato A; Casares de Cal Mde L; Abal M; López-López R
Int J Cancer; 2014 Dec; 135(11):2633-43. PubMed ID: 24752533
[TBL] [Abstract][Full Text] [Related]
6. Circulating tumor cells as a prognostic marker for efficacy in the randomized phase III JO21095 trial in Japanese patients with HER2-negative metastatic breast cancer.
Iwata H; Masuda N; Yamamoto D; Sagara Y; Sato N; Yamamoto Y; Saito M; Fujita T; Oura S; Watanabe J; Tsukabe M; Horiguchi K; Hattori S; Matsuura Y; Kuroi K
Breast Cancer Res Treat; 2017 Apr; 162(3):501-510. PubMed ID: 28181129
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of circulating tumour cells in limited-stage small-cell lung cancer: analysis of the concurrent once-daily versus twice-daily radiotherapy (CONVERT) randomised controlled trial.
Tay RY; Fernández-Gutiérrez F; Foy V; Burns K; Pierce J; Morris K; Priest L; Tugwood J; Ashcroft L; Lindsay CR; Faivre-Finn C; Dive C; Blackhall F
Ann Oncol; 2019 Jul; 30(7):1114-1120. PubMed ID: 31020334
[TBL] [Abstract][Full Text] [Related]
8. A Randomized Phase II Study of FOLFOX With or Without the MET Inhibitor Onartuzumab in Advanced Adenocarcinoma of the Stomach and Gastroesophageal Junction.
Shah MA; Cho JY; Tan IB; Tebbutt NC; Yen CJ; Kang A; Shames DS; Bu L; Kang YK
Oncologist; 2016 Sep; 21(9):1085-90. PubMed ID: 27401892
[TBL] [Abstract][Full Text] [Related]
9. A pilot study assessing the incidence and clinical significance of circulating tumor cells in esophagogastric cancers.
Sclafani F; Smyth E; Cunningham D; Chau I; Turner A; Watkins D
Clin Colorectal Cancer; 2014 Jun; 13(2):94-9. PubMed ID: 24332356
[TBL] [Abstract][Full Text] [Related]
10. Prospective assessment of the prognostic value of circulating tumor cells and their clusters in patients with advanced-stage breast cancer.
Mu Z; Wang C; Ye Z; Austin L; Civan J; Hyslop T; Palazzo JP; Jaslow R; Li B; Myers RE; Jiang J; Xing J; Yang H; Cristofanilli M
Breast Cancer Res Treat; 2015 Dec; 154(3):563-71. PubMed ID: 26573830
[TBL] [Abstract][Full Text] [Related]
11. Longitudinal enumeration and cluster evaluation of circulating tumor cells improve prognostication for patients with newly diagnosed metastatic breast cancer in a prospective observational trial.
Larsson AM; Jansson S; Bendahl PO; Levin Tykjaer Jörgensen C; Loman N; Graffman C; Lundgren L; Aaltonen K; Rydén L
Breast Cancer Res; 2018 Jun; 20(1):48. PubMed ID: 29884204
[TBL] [Abstract][Full Text] [Related]
12. A Phase II Study of the c-Met Inhibitor Tivantinib in Combination with FOLFOX for the Treatment of Patients with Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal Junction, or Stomach.
Pant S; Patel M; Kurkjian C; Hemphill B; Flores M; Thompson D; Bendell J
Cancer Invest; 2017 Aug; 35(7):463-472. PubMed ID: 28662341
[TBL] [Abstract][Full Text] [Related]
13. Cryopreservation for delayed circulating tumor cell isolation is a valid strategy for prognostic association of circulating tumor cells in gastroesophageal cancer.
Brungs D; Lynch D; Luk AW; Minaei E; Ranson M; Aghmesheh M; Vine KL; Carolan M; Jaber M; de Souza P; Becker TM
World J Gastroenterol; 2018 Feb; 24(7):810-818. PubMed ID: 29467551
[TBL] [Abstract][Full Text] [Related]
14. Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial.
Catenacci DVT; Tebbutt NC; Davidenko I; Murad AM; Al-Batran SE; Ilson DH; Tjulandin S; Gotovkin E; Karaszewska B; Bondarenko I; Tejani MA; Udrea AA; Tehfe M; De Vita F; Turkington C; Tang R; Ang A; Zhang Y; Hoang T; Sidhu R; Cunningham D
Lancet Oncol; 2017 Nov; 18(11):1467-1482. PubMed ID: 28958504
[TBL] [Abstract][Full Text] [Related]
15. Perioperative platin-based chemotherapy for locally advanced esophagogastric adenocarcinoma: Postoperative chemotherapy has a substantial impact on outcome.
Glatz T; Bronsert P; Schäfer M; Kulemann B; Marjanovic G; Sick O; Hopt UT; Zirlik K; Makowiec F; Hoeppner J
Eur J Surg Oncol; 2015 Oct; 41(10):1300-7. PubMed ID: 26253194
[TBL] [Abstract][Full Text] [Related]
16. Results of docetaxel plus oxaliplatin (DOCOX) ± cetuximab in patients with metastatic gastric and/or gastroesophageal junction adenocarcinoma: results of a randomised Phase 2 study.
Richards D; Kocs DM; Spira AI; David McCollum A; Diab S; Hecker LI; Cohn A; Zhan F; Asmar L
Eur J Cancer; 2013 Sep; 49(13):2823-31. PubMed ID: 23747051
[TBL] [Abstract][Full Text] [Related]
17. Circulating tumor cells in newly diagnosed inflammatory breast cancer.
Mego M; Giordano A; De Giorgi U; Masuda H; Hsu L; Giuliano M; Fouad TM; Dawood S; Ueno NT; Valero V; Andreopoulou E; Alvarez RH; Woodward WA; Hortobagyi GN; Cristofanilli M; Reuben JM
Breast Cancer Res; 2015 Jan; 17(1):2. PubMed ID: 25572591
[TBL] [Abstract][Full Text] [Related]
18. Prognostic and predictive value of circulating tumor cells and CXCR4 expression as biomarkers for a CXCR4 peptide antagonist in combination with carboplatin-etoposide in small cell lung cancer: exploratory analysis of a phase II study.
Salgia R; Weaver RW; McCleod M; Stille JR; Yan SB; Roberson S; Polzer J; Flynt A; Raddad E; Peek VL; Wijayawardana SR; Um SL; Gross S; Connelly MC; Morano C; Repollet M; Sanders R; Baeten K; D'Haese D; Spigel DR
Invest New Drugs; 2017 Jun; 35(3):334-344. PubMed ID: 28299514
[TBL] [Abstract][Full Text] [Related]
19. Predictive and prognostic value of folate receptor-positive circulating tumor cells in small cell lung cancer patients treated with first-line chemotherapy.
Shen J; Zhao J; Jiang T; Li X; Zhao C; Su C; Zhou C
Oncotarget; 2017 Jul; 8(30):49044-49052. PubMed ID: 28467771
[TBL] [Abstract][Full Text] [Related]
20. [Efficacy of lobaplatin plus S-1 and the predictive value of circulating tumor cell in patients with advanced gastric cancer].
Feng Q; Zhao JR; Zhang AX; Li SL
Zhonghua Zhong Liu Za Zhi; 2018 Sep; 40(9):696-702. PubMed ID: 30293397
[No Abstract] [Full Text] [Related]
[Next] [New Search]
